supply

From pandemic shutdowns to geopolitical tensions, recent years have thrown our global supply chains into unexpected chaos. This turbulent period has taught both governments and organizations a crucial lesson: supply chain excellence depends not just on efficiency but on the ability to navigate disruptions through strategic risk management. By leveragingContinue Reading

Sundry Photography/iStock Editorial via Getty Images Prelude Therapeutics (NASDAQ:PRLD) has forged a deal with Merck (NYSE:MRK) to test its investigational SMARCA2 degrader in combination with the latter’s blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with SMARCA4-mutated cancers. Shares of Prelude Therapeutics (PRLD) climbed as much as 28% following the news.Continue Reading